Radboudumc and partners Innovation by Predica Diagnostics BV improves cervical cancer screening

26 July 2022

First investment from ION+2 innovation fund

A joint financing round from ION+2 and the Thematic Technology Transfer Medtech Fund (TTT Medtech) allows the further development of molecular diagnostic tests for different cancers by Predica Diagnostics (Nijmegen, NL). This spin-off from Radboudumc Holding has a first focus on improvement of cervical cancer screening, to prevent futile physical examinations of healthy women, saving time and costs and preventing unnecessary worries because of false positive tests. This is the first financing by the ION+2 fund, managed by Oost NL, and is the first joint investment of Oost NL and TTT Medtech. 
Dr. William Leenders, CSO of Predica Diagnostics and associate professor at Radboudumc: “After a positive HPV-test, scrapes are examined under the microscope for the presence of aberrant cells (the PAP-test). The PAP test is however not very sensitive and lacks sufficient positive and negative predictive power for reliable stratification of women who need treatment. This is a problem because all women with a positive PAP test are referred to a gynecologist for visual inspection of the cervix (colposcopy). Because the test that we are developing not only detects presence of an HPV, but also shows if the virus has initiated the cancer-forming process, our test result is more reliable than the PAP-test. Additionally, we can diagnose up to 750 cervical scrapes at once, making the cost-effective. In the end the test can prevent overdiagnosis and overtreatment of healthy women, resulting in lower health care costs, lower workload for clinicians and less false positive test results with associated unnecessary worries.”

Investment, a crucial step

Dr. Marco de Boer is CEO of Predica Diagnostics: “This investment is a crucial step for us. Our technology allows early detection and prevention of cancer. With that in mind, we can have big impact in health care worldwide.” Predica will perform clinical validation of the test in close collaboration with Radboudumc and other hospitals, among others in Germany.
Geert Corstens, investment manager Health at Oost NL: “Predica’s test can makes health care more efficient and can reduce health care costs, while taking away unnecessary worries of healthy women. This makes this a valuable investment, and we are very happy that we can contribute via the ION+2 fund.”
Margherita Marchetti, Investment Manager at Innovation Industries, who manages the TTT Medtech fund: “Molecular diagnostic tests such as those in development by Predica Diagnostics become more and more important for prevention, diagnostics and predicting best treatment for cancer patients. Predica Diagnostics’ technology is a ‘platform technology’, allowing future research on many other cancer types. This is an example of a highly promising innovation to which we gladly contribute via our TTT Medtech fund.”

Original source for this article

Related news items

Third Radboudumc Investment Day again well-attended

16 October 2023

On October 12, the Radboudumc Investment Day took place for the third time. Scientists, entrepreneurs and investors from the life sciences & health sector came together in the Radboudumc Experience Center to exchange knowledge, network and talk about new collaborations.

read more

Take Off 2 funding from NWO for Predica Diagnostics

30 June 2023

Predica Diagnostics just secured the Take Off 2 funding to accelerate development of their cervical (pre)cancer prediction test.

read more

Boosting the startup ecosystem in Nijmegen!

22 June 2023

TechleapNL, Radboud university, Radboudumc and the municipality of Nijmegen hosted a successful event where innovative health and hightech startups shared their view on the challenges and opportunities for the local startup ecosystem.

read more

Meet Healthy Ideas, Healthy Returns

2 June 2023

Do you have a golden idea to improve healthcare, but not the resources to realize it? Discover Healthy Ideas, Healthy Returns: a Benelux-wide public-private network offering opportunities for healthcare investments and propositions, among other things.

read more

Aftermovie Investment Day 2022 and a new date for 2023!

13 December 2022

Over 100 scientists, investors, and entrepreneurs came together to accelerate innovation in healthcare by creating new business opportunities and forging strong public-private partnerships.

read more

Successful matchmaking at Radboudumc Investment Day  

7 October 2022

On the 5th of October, over 100 scientists, investors and entrepreneurs came together at the second Radboudumc Investment Day, jointly hosted by Radboudumc, Oost NL and Briskr.

read more